Sign inJoin waitlistJoin the waitlist

Matthew Oser

Associate Professor of Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · ·

History

Dana-Farber Cancer Institute
2014–2016
Internal Medicine
Brigham and Women's Hospital
2011–2014
Albert Einstein College of Medicine
Albert Einstein College of Medicine
2007–2011

Research

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Review · The Lancet Oncology · 2015 · First of 4 authors · 798 citations
Polycomb group protein ezh2 controls actin polymerization and cell signaling
Cell · 2005 · 306 citations
Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation
The Journal of Cell Biology · 2009 · First of 10 authors · Corresponding · 304 citations

Sabina Signoretti
12 papers
David Barbie
8 papers
YL
Yasmin Laimon
8 papers
Bill Kaelin
7 papers
YD
Yavuz Durmaz
7 papers · 1 as a resident
Matthew Freedman
6 papers
Navin Mahadevan
6 papers
Jacob Berchuck
5 papers
TZ
Talal El Zarif
5 papers · 5 as a resident
Amin Sabet
4 papers
Charles Rudin
4 papers
Pasi Jänne
4 papers

Grants

TRIM28 Inhibition as a Synthetic Lethal Strategy for Small Cell Lung Cancers with NOTCH2-Inactivation
National Cancer Institute · R01
Contact PI · $609.1K · Dana-Farber Cancer Inst
2026–2031
Convergent Epigenetic Control of Neuroendocrine Cancers
National Cancer Institute · P01
Project lead · $1.2M · Dana-Farber Cancer Inst
2025–2030
Mechanisms by Which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
National Cancer Institute · R37
Contact PI · $1.8M · Dana-Farber Cancer Inst
2022–2027
New Therapeutic Targets in Small Cell Lung Cancer That Are Epistatic or Synthetic Lethal with pRB Loss
National Cancer Institute · K08
Contact PI · $885.6K · Dana-Farber Cancer Inst
2017–2022